Mannatech, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter earnings report. Unless otherwise noted, comparisons are with FY 2015; amounts are U.S. dollars.
Business context
Mannatech develops and sells nutritional supplements, skin care, anti-aging, weight-management and related products, primarily through independent associates and members in 25 countries. It reported approximately 222,000 active associate and member positions, versus 219,000 in 2015. In 2016, it also began China retail sales through a cross-border e-commerce subsidiary; this operation is not direct selling or multi-level marketing.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Net sales | $180.3 million | $180.3 million |
| Gross profit / margin | $143.7 million / 79.7% | $146.2 million / 81.1% |
| Operating income / margin | $0.7 million / 0.4% | $12.1 million / 6.7% |
| Net income (loss) | $(0.6) million | $5.8 million |
| Basic and diluted EPS | $(0.22) | $2.18 / $2.14 |
| Cash from operating activities | $(0.023) million | $4.4 million |
Net sales were essentially flat on a reported basis; at constant currency, they increased 0.9%. Gross margin declined amid promotional discounting, higher transportation costs and foreign exchange effects. Operating expenses rose 6.7% to $143.0 million, including higher legal and consulting, associate-event travel, payroll and marketing costs. Other expense included a $1.8 million foreign-exchange loss, compared with $4.2 million in 2015.
Asia/Pacific sales rose 5.3% to $96.2 million; Americas sales fell 4.2% to $70.2 million; EMEA sales fell 10.9% to $13.9 million. Product sales increased 3.8% to $148.6 million, while pack sales declined 15.8% to $26.7 million. Management attributed higher product sales primarily to a larger average order value ($166 versus $155), despite 3.4% fewer orders.
Cash and cash equivalents were $28.7 million at year-end, down from $32.0 million; total restricted cash was approximately $7.9 million. Working capital was $20.8 million, down from $23.5 million. Current assets were $50.8 million and current liabilities $30.0 million. Notes payable totaled $1.4 million and capital lease obligations $0.6 million. The filing reports no off-balance-sheet arrangements. Operating cash flow was nearly breakeven, versus $4.4 million provided in 2015; investing used $2.3 million and financing used $2.5 million in 2016.
Material changes and unusual items
- Revenue from five key products was $90.9 million, or 50.4% of sales, versus $85.5 million, or 47.4%, in 2015. Advanced Ambrotose alone generated 31.0% of sales.
- Commissions and incentives were $74.2 million, or 41.2% of sales, versus $73.0 million, or 40.5%, in 2015. Management states the combined rate typically ranges from 39% to 43%.
- Net sales were affected by new products and promotions ($11.1 million of 2016 sales) and loyalty-program revenue recognition. Excluding the listed comparability effects, management said sales would have decreased by $10.5 million.
- The company recorded a $0.4 million charge for abandoned internally developed software. Inventory increased to $12.0 million from $9.2 million, while the inventory obsolescence reserve declined to $0.4 million from $1.3 million.
- Foreign exchange reduced reported 2016 sales by $1.7 million versus 2015. Approximately 70.5% of sales were outside the United States; the company does not hedge currency risk.
- The company paid $0.7 million in dividends in 2016, versus none in 2015, and repurchased $0.3 million of shares during the year.
Outlook, risks and contingencies
Management expects existing liquidity and operating cash flows to fund normal operations for the next 12 months and believes operating cash flows should support longer-term needs. This outlook depends on maintaining or improving revenue relative to expenses; management cautions that additional financing may be needed if cash resources prove insufficient and may not be available on favorable terms. No numerical earnings or revenue guidance is provided.
- Management disclosed plans to modify the associate compensation plan during 2017, with uncertain effects on associate retention, revenue and profitability.
- A four-year aloe supply agreement requires approximately $19.0 million of purchases through 2020. The filing also identifies Arabinogalactan as an important Ambrotose ingredient for which no alternative supplier had been identified.
- An open Texas contract case sought approximately $0.6 million in past commissions and $2.0–$3.1 million in future commissions. A court ruling on contract interpretation favored the plaintiffs; trial was scheduled for June 2017. The company said the outcome and potential damages could not be estimated.
- A Korean customs assessment of $1.0 million, already paid, was under appeal after a trial-level decision favored the company. A patent infringement case was in the damages phase. The filing also describes an ongoing trademark opposition.
- Other significant risks include regulatory limits on supplements and network marketing, improper claims or conduct by independent associates, reliance on a concentrated product range, competitive and economic pressures, currency movements, cybersecurity and supplier interruptions, and tax audits or transfer-pricing challenges.
Most important facts for investors to verify
- Whether subsequent filings show sustained sales, margins and operating cash flow improvement after the sharp FY 2016 earnings decline.
- Results of the 2017 compensation-plan changes and their impact on associate activity, retention and the 39%–43% commission-and-incentive burden.
- Developments and any financial exposure from the Texas litigation, Korean customs appeal, patent damages proceedings and trademark dispute.
- Progress and profitability of China’s cross-border e-commerce operation, including any regulatory or licensing changes.
- Cash needs and fulfillment of the $19.0 million aloe purchase commitment, alongside the company’s foreign-currency exposure and limited cash generation.
- The assumptions supporting deferred tax asset realization and the status of tax audits and uncertain tax positions.
The financial statements received an unqualified audit opinion from BDO USA, LLP. Management concluded internal control over financial reporting was effective as of December 31, 2016; the auditor stated it was not engaged to audit internal control.